Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of…
Ascletis Pharma Inc. announces the approval of the Investigational New Drug (IND) application by China National Medical Products Administration (NMPA) for the in-house developed oral…
Read More...
Read More...
